Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Retained Earnings (2021 - 2026)

Nuvectis Pharma has reported Retained Earnings over the past 6 years, most recently at -$105.7 million for Q1 2026.

  • Quarterly results put Retained Earnings at -$105.7 million for Q1 2026, down 34.48% from a year ago — trailing twelve months through Mar 2026 was -$105.7 million (down 34.48% YoY), and the annual figure for FY2025 was -$99.7 million, down 36.1%.
  • Retained Earnings reached -$105.7 million in Q1 2026 per NVCT's latest filing, down from -$99.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$15.8 million in Q1 2022 and bottomed at -$105.7 million in Q1 2026.
  • Median Retained Earnings over the past 5 years was -$58.4 million (2024), compared with a mean of -$58.5 million.
  • The largest annual shift saw Retained Earnings plummeted 147.95% in 2022 before it plummeted 34.48% in 2026.
  • Over 5 years, Retained Earnings stood at -$32.0 million in 2022, then tumbled by 69.6% to -$54.2 million in 2023, then plummeted by 35.03% to -$73.2 million in 2024, then tumbled by 36.1% to -$99.7 million in 2025, then dropped by 6.03% to -$105.7 million in 2026.
  • Business Quant data shows Retained Earnings for NVCT at -$105.7 million in Q1 2026, -$99.7 million in Q4 2025, and -$92.4 million in Q3 2025.